The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience
Sandy Bohan et al.

Supplemental Table 1. Tumor Types of Consented Patients in the I-PREDICT Trial (University of California San Diego site)

Parameter	Evaluable	Inevaluable	Awaiting Treatment
Consented, *N* = 190	99 (52%)	83 (44%)	8 (4%)
Tumor type			
Blood, *n* = 3 (1%)	1 (33%)	2 (67%)	0
Breast, *n* = 5 (3%)	4 (80%)	1 (20%)	0
Central Nervous System, *n* = 7 (4%)	5 (71%)	2 (29%)	0
Endocrine, Neuroendocrine, *n* = 6 (3%)	3 (50%)	2 (33%)	1 (17%)
Gastrointestinal[a], *n* = 103 (54%)	50 (49%)	49 (47%)	4 (4%)
Genitourinary, *n* = 5 (3%)	3 (60%)	2 (40%)	0
Gynecological, *n* = 27 (14%)	13 (48%)	12 (45%)	2 (7%)
Lung, *n* = 3 (1%)	2 (67%)	1 (33%)	0
Mesothelioma, *n* = 2 (1%)	0	2 (100%)	0
Oral, Head, and Neck; *n* = 10 (5%)	6 (60%)	3 (30%)	1 (10%)
Soft Tissue Sarcoma, *n* = 18 (10%)	11 (61%)	7 (39%)	0
Unspecified site, *n* = 1 (1%)	1 (100%)	0	0

Note: Data for evaluable, inevaluable, and awaiting treatment are presented as *n* (%) of the tumor type.

[a]Gastrointestinal tumor type includes hepatobiliary (16%, *n* = 16 of 103 patients) and pancreatic cancers (12%, *n* = 12 of 103 patients).